Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$59.92 USD

59.92
2,129,566

-0.03 (-0.05%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $59.91 -0.01 (-0.02%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

by Zacks Equity Research

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

by Zacks Equity Research

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?

by Zacks Equity Research

Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

by Zacks Equity Research

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Stock Market News for Jan 8, 2024

by Zacks Equity Research

Wall Street closed higher after a choppy session on Friday to finish the first week of 2024.

Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Catalent (CTLT) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Stock Market News for Nov 16, 2023

by Zacks Equity Research

Wall Street closed higher on Wednesday after a sharp rally in the previous day.

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

by Zacks Equity Research

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) fiscal Q1 results are likely to be affected by soft performance by the Biologics segment.

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 37.50% and 389.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity's (RVTY) New Launch to Widen Access to Editing Technology

by Zacks Equity Research

Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.

Catalent (CTLT) Down 6.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Compared to Estimates, Catalent (CTLT) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.